TY - JOUR
T1 - Coronary artery plaque progression and cardiovascular risk scores in men with and without HIV-infection
AU - Shaikh, Kashif
AU - Bhondoekhan, Fiona
AU - Haberlen, Sabina
AU - Nakanishi, Rine
AU - Roy, Sion K.
AU - Alla, Venkata M.
AU - Brown, Todd T.
AU - Lee, Juhwan
AU - Osawa, Kazuhiro
AU - Almeida, Shone
AU - Rahmani, Sina
AU - Nezarat, Negin
AU - Sheidaee, Nasim
AU - Kim, Michael
AU - Jayawardena, Eranthi
AU - Kim, Nicolas
AU - Hathiramani, Nicolai
AU - Palella, Frank J.
AU - Witt, Mallory
AU - Ahmad, Khadije
AU - Kingsley, Lawrence
AU - Post, Wendy S.
AU - Budoff, Matthew J.
N1 - Funding Information:
The MACS coronary CT angiography studies are funded by National Heart Lung and Blood Institute (NHLBI) RO1 HL095129 (Post) and R01 HL125053 (Post). Data in this manuscript were collected by the MACS, now the MACS/WIHS Combined Cohort Study (MWCCS). U01-HL146201, U01-HL146193, U01-HL146245, U01-HL146240, U01-HL146333, U01-HL146208. The MWCCS is funded primarily by the National Heart, Lung, and Blood Institute (NHLBI), with additional co-funding NICHD, NIDCR, NIAID, NINDS, NIMH, NIDA, NINR, NCI, NIAAA, NIDCD, NIDDK, NIMHD. MWCCS data collection is also supported by UL1TR003098 (JHU ICTR), UL1-TR000004 (UCSF CTSA), UL1- TR001881 (UCLA-CTSI).
Funding Information:
The MACS coronary CT angiography studies are funded by National Heart Lung and Blood Institute (NHLBI) RO1 HL095129 (Post) and R01 HL125053 (Post). Data in this manuscript were collected by the MACS, now the MACS/WIHS Combined Cohort Study (MWCCS). U01-HL146201, U01-HL146193, U01-HL146245, U01-HL146240, U01-HL146333, U01-HL146208. The MWCCS is funded primarily by the National Heart, Lung, and Blood Institute (NHLBI), with additional co-funding NICHD, NIDCR, NIAID, NINDS, NIMH, NIDA, NINR, NCI, NIAAA, NIDCD, NIDDK, NIMHD. MWCCS data collection is also supported by UL1TR003098 (JHU ICTR), UL1-TR000004 (UCSF CTSA), UL1-TR001881 (UCLACTSI).
Publisher Copyright:
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Objective: The aim of this study was to assess the association of cardiovascular disease (CVD) risk scores and coronary artery plaque (CAP) progression in HIV-infected participants. Methods: We studied men with and without HIV-infection enrolled in the Multicenter AIDS Cohort Study (MACS) CVD study. CAP at baseline and follow-up was assessed with cardiac computed tomography angiography (CCTA). We examined the association between baseline risk scores including pooled cohort equation (PCE), Framingham risk score (FRS), and Data collect of Adverse effects of anti-HIV drugs equation (D:A:D) and CAP progression. Results: We studied 495 men (211 HIV-uninfected, 284 HIV-infected). The adjusted odds ratio (aOR) of total plaque volume (TPV) and noncalcified plaque volume (NCPV) progression in the highest relative to lowest tertile was 9.4 [95% confidence interval (95% CI) 2.4 – 12.1, P < 0.001)] and 7.7 (95% CI 3.1 – 19.1, P < 0.001) times greater, respectively, among HIV-uninfected men in the PCE atherosclerotic cardiovascular disease (ASCVD) high vs. low-risk category. Among HIV-infected men, the association for TPV and NCPV progression for the same PCE risk categories, odds ratio (OR) 2.8 (95% CI 1.4 – 5.8, P < 0.01) and OR 2.4 (95% CI 1.2 – 4.8, P < 0.05), respectively (P values for interaction by HIV = 0.02 and 0.08, respectively). Similar results were seen for the FRS risk scores. Among HIV-uninfected men, PCE high risk category identified the highest proportion of men with plaque progression in the highest tertile, although in HIV-infected men, high-risk category by D:A:D identified the greatest percentage of men with plaque progression albeit with lower specificity than FRS and PCE. Conclusion: PCE and FRS categories predict CAP progression better in HIV-uninfected than in HIV-infected men. Improved CVD risk scores are needed to identify high-risk HIV-infected men for more aggressive CVD risk prevention strategies.
AB - Objective: The aim of this study was to assess the association of cardiovascular disease (CVD) risk scores and coronary artery plaque (CAP) progression in HIV-infected participants. Methods: We studied men with and without HIV-infection enrolled in the Multicenter AIDS Cohort Study (MACS) CVD study. CAP at baseline and follow-up was assessed with cardiac computed tomography angiography (CCTA). We examined the association between baseline risk scores including pooled cohort equation (PCE), Framingham risk score (FRS), and Data collect of Adverse effects of anti-HIV drugs equation (D:A:D) and CAP progression. Results: We studied 495 men (211 HIV-uninfected, 284 HIV-infected). The adjusted odds ratio (aOR) of total plaque volume (TPV) and noncalcified plaque volume (NCPV) progression in the highest relative to lowest tertile was 9.4 [95% confidence interval (95% CI) 2.4 – 12.1, P < 0.001)] and 7.7 (95% CI 3.1 – 19.1, P < 0.001) times greater, respectively, among HIV-uninfected men in the PCE atherosclerotic cardiovascular disease (ASCVD) high vs. low-risk category. Among HIV-infected men, the association for TPV and NCPV progression for the same PCE risk categories, odds ratio (OR) 2.8 (95% CI 1.4 – 5.8, P < 0.01) and OR 2.4 (95% CI 1.2 – 4.8, P < 0.05), respectively (P values for interaction by HIV = 0.02 and 0.08, respectively). Similar results were seen for the FRS risk scores. Among HIV-uninfected men, PCE high risk category identified the highest proportion of men with plaque progression in the highest tertile, although in HIV-infected men, high-risk category by D:A:D identified the greatest percentage of men with plaque progression albeit with lower specificity than FRS and PCE. Conclusion: PCE and FRS categories predict CAP progression better in HIV-uninfected than in HIV-infected men. Improved CVD risk scores are needed to identify high-risk HIV-infected men for more aggressive CVD risk prevention strategies.
KW - Calcified plaque
KW - Cardiovascular disease risk
KW - HIV
KW - Noncalcified
UR - http://www.scopus.com/inward/record.url?scp=85122299715&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122299715&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000003093
DO - 10.1097/QAD.0000000000003093
M3 - Article
C2 - 34608042
AN - SCOPUS:85122299715
SN - 0269-9370
VL - 36
SP - 215
EP - 224
JO - AIDS
JF - AIDS
IS - 2
ER -